title: Long-term administration of beraprost sodium for pulmonary arterial hypertension associated with congenital heart disease.
abstract: Pulmonary arterial hypertension (PAH) is often associated with congenital heart disease (CHD). Acute administration of beraprost reduces pulmonary vascular resistance in patients with idiopathic PAH and PAH associated with CHD; however, little is known about whether or not long-term treatment with oral beraprost benefits these patients. We report the case of a patient suffering from severe PAH associated with large patent ductus arteriosus (PDA), who was considered to be ineligible for PDA closure using a conventional treatment strategy. Eventually, long-term administration of oral beraprost ameliorated the degree of PAH and the patient subsequently underwent successful closure of the PDA.
authors.affiliation: Pediatrics, Reproductive and Developmental Medicine, Akita University, Akita. jun@doc.med.akita-u.ac.jp
authors.forename: Jun
authors.initials: J
authors.lastname: Oyamada
authors.forename: Manatomo
authors.initials: M
authors.lastname: Toyono
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Shimada
authors.forename: Mieko
authors.initials: M
authors.lastname: Aoki-Okazaki
authors.forename: Masamichi
authors.initials: M
authors.lastname: Tamura
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D002675:Child, Preschool; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D008297:Male
chemical_list: C048081:beraprost; D011464:Epoprostenol